Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

antifungal/atrofija

Nuoroda įrašoma į mainų sritį
Puslapis 1 nuo 23499 rezultatus

Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA)

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Spinal and bulbar muscular atrophy (SBMA) is a hereditary neuromuscular disorder caused by CAG trinucleotide expansion in the gene encoding the androgen receptor (AR). In the central nervous system, lower motor neurons are selectively affected, whereas pathology of patients and animal models

Retinoid analogs and polyphenols as potential therapeutics for age-related macular degeneration

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Age-related macular degeneration (AMD) is a devastating retinal degenerative disease. Epidemiological reports showed an expected increasing prevalence of AMD in the near future. The only one existing FDA-approved pharmacological treatment involves an anti-vascular endothelial growth factor (VEGF)

Wallerian degeneration as a therapeutic target in traumatic brain injury.

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Diffuse or traumatic axonal injury is one of the principal pathologies encountered in traumatic brain injury (TBI) and the resulting axonal loss, disconnection, and brain atrophy contribute significantly to clinical morbidity and disability. The seminal discovery of the slow Wallerian

Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration.

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Ataxia-telangiectasia (A-T) is an autosomal recessive disorder characterized by cerebellar ataxia and oculocutaneous telangiectasias. The gene mutated in this disease, Atm (A-T mutated), encodes a serine/threonine protein kinase that has been traditionally considered to be a nuclear protein

MicroRNA as Therapeutics for Age-Related Macular Degeneration.

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
MicroRNA (miRNA) are a class of endogenously expressed small non-coding RNA molecules that function by repressing or silencing post-transcriptional gene expression. While miRNAs were only identified in humans as recently as the turn of this century, some miRNA-based agents are already in Phase 2

Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging.

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Age-related macular degeneration is the leading cause of irreversible visual dysfunction in individuals over 65 in Western Society. Patients with AMD are classified as having early stage disease (early AMD), in which visual function is affected, or late AMD (generally characterized as either "wet"

Therapeutic advances in 5q-linked spinal muscular atrophy.

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Spinal muscular atrophy (SMA) is a severe and clinically-heterogeneous motor neuron disease caused, in most cases, by a homozygous mutation in the SMN1 gene. Regarding the age of onset and motor involvement, at least four distinct clinical phenotypes have been recognized. This clinical variability

Therapeutic effect of psoralen on muscle atrophy induced by tumor necrosis factor-α.

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
To observe and determine the effect and mechanism of psoralen on tumor necrosis factor-α (TNF-α)-induced muscle atrophy.Three sets of C2C12 cells, including blank control, TNF-α (10 or 20 ng/ml) treatment and a TNF-α (10 or 20 ng/ml) plus psoralen (80 μM)

Invertebrate models of spinal muscular atrophy: insights into mechanisms and potential therapeutics.

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Invertebrate genetic models with their tractable neuromuscular systems are effective vehicles for the study of human nerve and muscle disorders. This is exemplified by insights made into spinal muscular atrophy (SMA) using the fruit fly Drosophila melanogaster and the nematode worm Caenorhabditis

DcpS as a therapeutic target for spinal muscular atrophy.

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Spinal muscular atrophy (SMA) is caused by deletion or mutation of both copies of the SMN1 gene, which produces an essential protein known as SMN. The severity of SMA is modified by variable copy number of a second gene,SMN2, which produces an mRNA that is incorrectly spliced with deletion of the

Erythropoietin as a novel therapeutic agent for atrophic age-related macular degeneration.

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The purpose of this article is to propose a novel therapeutic approach to the treatment of age-related macular degeneration (ARMD), the leading cause of blindness in the elderly population (over 60 years of age) in developed countries. Although recent advances have been made in the treatment of the

Spinal muscular atrophy disease: a literature review for therapeutic strategies.

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Currently, there is no cure for the treatment of spinal muscular atrophy (SMA). Based on the available clinical and molecular findings, different therapeutic strategies were tested in vitro and in vivo and clinical trials are ongoing. The main therapeutic direction is focused on the enhancement of

Is spinal muscular atrophy a disease of the motor neurons only: pathogenesis and therapeutic implications?

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Spinal muscular atrophy (SMA) is a genetic neurological disease that causes infant mortality; no effective therapies are currently available. SMA is due to homozygous mutations and/or deletions in the survival motor neuron 1 gene and subsequent reduction of the SMN protein, leading to the death of

Histamime Receptor H4 as a New Therapeutic Target for Age-related Macular Degeneration.

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Histamine receptor H4 (HRH4) is one of four known histamine receptors, among which H1 receptor is primarily involved in typeI allergic reactions and H2 receptor is generally recognized for its role in gastric acid secretion. Compared with H1 and H2, HRH4 has unique characteristics; it is expressed

Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
We review the genetic and clinical features of spinobulbar muscular atrophy (SBMA), a progressive neuromuscular disorder caused by a CAG/glutamine tract expansion in the androgen receptor. SBMA was the first polyglutamine disease to be discovered, and we compare and contrast it with related
Prisijunkite prie mūsų
„Facebook“ puslapio

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

  • Dirba 55 kalbomis
  • Žolelių gydymas, paremtas mokslu
  • Vaistažolių atpažinimas pagal vaizdą
  • Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
  • Skaitykite mokslines publikacijas, susijusias su jūsų paieška
  • Ieškokite vaistinių žolelių pagal jų poveikį
  • Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais

Google Play badgeApp Store badge